Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients

[1]  F. Puntillo,et al.  High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[3]  Miguel Calvo Rebollar,et al.  Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. , 2011, The Journal of antimicrobial chemotherapy.

[4]  L. Pagano,et al.  Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies , 2011, Haematologica.

[5]  H. Giamarellou.  Multidrug-resistant Gram-negative bacteria: how to treat and for how long. , 2010, International journal of antimicrobial agents.

[6]  M. Aricò,et al.  Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation , 2010, Haematologica.

[7]  Á. Soriano,et al.  Influence of Empiric Therapy with a β-Lactam Alone or Combined with an Aminoglycoside on Prognosis of Bacteremia Due to Gram-Negative Microorganisms , 2010, Antimicrobial Agents and Chemotherapy.

[8]  P. Singer,et al.  Effectiveness and safety of colistin: prospective comparative cohort study. , 2010, The Journal of antimicrobial chemotherapy.

[9]  A. Nagler,et al.  Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience , 2010, Infection.

[10]  Yee-Chun Chen,et al.  Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. , 2010, International journal of antimicrobial agents.

[11]  M. Falagas,et al.  Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. , 2010, International journal of antimicrobial agents.

[12]  F. Gudiol,et al.  Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. , 2010, The Journal of antimicrobial chemotherapy.

[13]  E. D’Agata,et al.  Erratum: Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients (Transplant Infectious Disease (2009) 11:3 (227-234) DOI: 10.1111/j.1399-3062.2009.00380.x) , 2009 .

[14]  Joshua D. Hartzell,et al.  Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Paterson,et al.  Pseudomonas aeruginosa bacteremia over a 10‐year period: multidrug resistance and outcomes in transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[16]  M. Falagas,et al.  Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. , 2009, International journal of antimicrobial agents.

[17]  A. Armaganidis,et al.  Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[18]  P. Chiusolo,et al.  Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. , 2009, The Journal of infection.

[19]  G. Maartens,et al.  Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections , 2009, BMC infectious diseases.

[20]  Á. Soriano,et al.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. , 2009, The Journal of antimicrobial chemotherapy.

[21]  M. Falagas,et al.  Intravenous Colistimethate (Colistin) Use in Critically Ill Children Without Cystic Fibrosis , 2009, The Pediatric infectious disease journal.

[22]  Gopi Patel,et al.  Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.

[23]  K. Rolston,et al.  Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  P. Muñoz,et al.  Bloodstream Infections Among Transplant Recipients: Results of a Nationwide Surveillance in Spain 1 , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  K. Rolston,et al.  Risk factors for infections with multidrug‐resistant Stenotrophomonas maltophilia in patients with cancer , 2007, Cancer.

[26]  Â. Maiolino,et al.  Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients , 2007, Bone Marrow Transplantation.

[27]  G. Bodey,et al.  Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa in Cancer Patients , 2007, Antimicrobial Agents and Chemotherapy.

[28]  M. Falagas,et al.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. , 2006, Clinical medicine & research.

[29]  J. Tarrand,et al.  Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients , 2006, Cancer.

[30]  M. Falagas,et al.  Toxicity of polymyxins: a systematic review of the evidence from old and recent studies , 2006, Critical care.

[31]  G. Fadda,et al.  Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome , 2006, Antimicrobial Agents and Chemotherapy.

[32]  Y. Kanda,et al.  Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  R. Ramphal,et al.  Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  R. Salazar,et al.  Bacteraemia Caused by Non-Glucose-Fermenting Gram-Negative Bacilli and Aeromonas Species in Patients with Haematological Malignancies and Solid Tumours , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[35]  L. Elting,et al.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  L. Leibovici,et al.  Colistin: new lessons on an old antibiotic. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  B. Labar,et al.  Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. , 2011, Internal medicine.

[38]  D. Paterson,et al.  Critically-Ill Patients from a Multi-Center Study Provide Dosing Suggestions for Various , 2011 .

[39]  C. Viscoli,et al.  Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  H. Ariffin,et al.  Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. , 2000, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.